Clinical Trial

Disease: Advanced or Metastatic melanoma, (2023-510417-25-00)

Disease info:

A solid tumour is an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumours may be benign (not cancer), or malignant (cancer). Solid tumour types are named according to the type of cell they originate from. Examples of solid tumours include melanomas, sarcomas, carcinomas and lymphomas. 

This trial is specifically targeting patients with advanced or metastatic (progressive) melanoma. Melanoma is a rare form of skin cancer.

 

 

Frequency:
The American Cancer Society estimates that in 2025, about 104,960 new melanoma cases will be diagnosed in the United States, and approximately 8,430 people are expected to die from the disease.
Official title:
CRISPR-TIL for metastatic melanoma
Who:

Contact

Name: Joel Emanuel Jörn

Phone: 38689198

Email: joel.emanuel.joern@regionh.dk

 

Name: Prof. Inge Marie Svane

Phone: 38682131    

Email: inge.marie.svane@regionh.dk
 

Sponsor:

Herlev Hospital

Partners:
Locations:

Herlev, Denmark

Herlev Hospital, Borgmester Ib Juuls Vej 1, Borgmester Ib Juuls Vej 1, Herlev, 2730, Denmark    

Study start:
Dec. 6, 2024
Enrollment:
Gene editing method:
CRISPR-Cas9
Type of edit:
Gene knockout
Gene:
Programmed cell death protein 1 (PD-1)
Delivery method:
Electroporation - Ex-vivo
Trial link:
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-510417-25-00
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting

Description

This is a phase 1 trial to investigate CRISPR-Cas9 edited tumour-infiltrating lymphocytes (TILs) expressing PDL-1 knockdown in advanced or metastatic melanoma.

Last updated: Feb. 24, 2025
close
Search CRISPR Medicine